



PRESS RELEASE

September 27, 2022

CombiGene strengthens its management capacity through the recruitment of Peter Ekolind as COO

STOCKHOLM — On September 27, 2022, CombiGene ("CombiGene", the "Company") announced that Peter Ekolind joins the Company September 27, 2022, when he assumes the position of Chief Operating Officer, initially as a part-time assignment.

Peter Ekolind has extensive leadership experience from the pharmaceutical and medtech industries. Many years of work in a variety of positions have given Peter a good knowledge of product development, sales, marketing preclinical development and GMP manufacturing. Peter has held several senior positions as, among other things, business area manager, COO and CEO. He has, in everything from large multi-international companies to small development companies, worked with business development, capitalization, internationalization, change management, innovation issues, public procurement, negotiation and research collaborations with universities and colleges.

"I am very happy to come to CombiGene at this very exciting stage," says Peter Ekolind. "I am impressed with how the team at CombiGene has in a short time established the company in the international gene therapy market. I am really looking forward to contributing to making CombiGene an even stronger and more attractive company."

"With his broad experience, Peter Ekolind will strengthen our management capacity as we have now intensified our efforts to expand our project portfolio with new and promising gene therapy candidates," says Jan Nilsson, CombiGene's CEO.

About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to preclinical/clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations.

The Company has signed an exclusive collaboration and licensing agreement for CombiGene's CG01 project with Spark Therapeutics.

The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, info@fnca.se.

For more information:

CombiGene AB (publ)

Jan Nilsson, CEO

Phone: +46 (0)704 66 31 63

jan.nilsson@combigene.com

Bert Junno, Chairman of the Board

Phone: +46(0) 70 7 77 22 09

bert.junno@combigene.com